Particle.news
Download on the App Store
4 ARTICLES
·
4w ago

ArcaScience Raises $7 Million Seed to Expand AI Drug Benefit–Risk Platform

The Paris startup touts a 24-model system trained on 100 billion datapoints to accelerate benefit–risk decisions in drug development.

Screenshot for ArcaScience Secures $7M for AI Drug Development Platform Expansion

Overview

  • Lead investor The Moon Venture was joined by Pléiade Venture, Plug & Play Ventures, Bpifrance, and AKKA Technologies in the round.
  • The company plans U.S. and U.K. expansion, a Chief Medical Officer hire, and its first patient-facing product focused initially on pediatric brain cancer and dermatology.
  • ArcaScience reports early adoption by pharma clients including Sanofi, AstraZeneca, GSK, Takeda, and ICON, plus work with the Paris Brain Institute.
  • The platform was used by the French government during COVID-19 to organize and analyze the scientific literature, and the company cites support for more than 70,000 patients.
  • This first institutional round follows a €1.3 million pre-seed, with the company also stating it has reached break-even twice since late 2024.